Description

Microarray Panel:Lung cancerNo. of samples59No. of patients59Core diameter2.0 mmFormat:Formalin FixedSection thickness 4 micrometer Core# No. Age Sex Organ Diagnosis LN* pTNM Stage No. of CCN5# Tissuetype Image 1 56 M Lung squamous cell carcinoma, well differentiated 5/43 T2aN1M0 IIA 101 6 " class="fd_image"> 2 47 F Lung adenocarcinoma, moderately differentiated 0/30 T2aN0M0 IB 102 6 " class="fd_image"> 3 34 F Lung adenocarcinoma, well differentiated 18/30 T2bN2M0 IIIA 103 6 " class="fd_image"> 4 69 F Lung adenocarcinoma, well differentiated 0/15 T2aN0M0 IB 104 6 " class="fd_image"> 5 59 M Lung squamous cell carcinoma, moderately differentiated 1/15 T2bN1M0 IIB 105 6 " class="fd_image"> 6 62 M Lung squamous cell carcinoma, moderately differentiated 0/8 T2aN0M0 IB 106 6 " class="fd_image"> 7 42 M Lung bronchioloalveolar carcinoma, non-mucinous 7/17 T3N2M0 IIIA 107 6 " class="fd_image"> 8 64 M Lung adenocarcinoma, well differentiated 0/39 T2aN0M0 IB 108 6 " class="fd_image"> 9 64 M Lung squamous cell carcinoma, well differentiated 0/15 T2aN0M0 IB 109 6 " class="fd_image"> 10 68 M Lung squamous cell carcinoma, moderately differentiated 0/16 T3N0M0 IIB 110 6 " class="fd_image"> 11 54 M Lung carcinosarcoma 0/6 T3N0M0 IIB 111 6 " class="fd_image"> 12 73 M Lung large cell neuroendocrine carcinoma 0/7 T2aN0M0 IB 112 6 " class="fd_image"> 13 66 M Lung squamous cell carcinoma, well differentiated 2/20 T3N2M0 IIIA 113 6 " class="fd_image"> 14 59 F Lung large cell carcinoma 0/9 T2aN0M0 IB 114 6 " class="fd_image"> 15 59 M Lung squamous cell carcinoma, well differentiated 4/61 T2aN1M0 IIA 115 6 " class="fd_image"> 16 65 M Lung bronchioloalveolar carcinoma, non-mucinous 0/8 T2bN0M0 IIA 116 6 " class="fd_image"> 17 64 M Lung bronchioloalveolar carcinoma, mucinous 0/8 T2aN0M0 IB 117 6 " class="fd_image"> 18 61 M Lung squamous cell carcinoma, moderately differentiated 0/16 T2aN0M0 IB 118 6 " class="fd_image"> 19 69 F Lung squamous cell carcinoma, moderately differentiated 0/34 T2bN0M0 IIA 119 6 " class="fd_image"> 20 64 M Lung squamous cell carcinoma, well differentiated 0/17 T2aN0M0 IB 120 6 " class="fd_image"> 21 74 M Lung squamous cell carcinoma, well differentiated 1/46 T2bN1M0 IIB 121 6 " class="fd_image"> 22 53 F Lung squamous cell carcinoma, spindle cell 0/10 T1bN0M0 IA 122 6 " class="fd_image"> 23 61 M Lung squamous cell carcinoma, well differentiated 1/43 T2aN1M0 IIA 123 6 " class="fd_image"> 24 59 F Lung bronchioloalveolar carcinoma, mucinous 0/24 T2aN0M0 IB 124 6 " class="fd_image"> 25 58 M Lung large cell carcinoma 0/14 T1bN0M0 IA 125 6 " class="fd_image"> 26 77 M Lung squamous cell carcinoma, moderately differentiated 5/18 T2aN2M0 IIIA 126 6 " class="fd_image"> 27 53 F Lung bronchioloalveolar carcinoma, mucinous 0/9 T3N0M0 IIB 127 6 " class="fd_image"> 28 72 M Lung squamous cell carcinoma, poorly differentiated 0/18 T2bN0M0 IIA 128 6 " class="fd_image"> 29 63 M Lung squamous cell carcinoma, moderately differentiated 1/25 T2aN1M0 IIA 129 6 " class="fd_image"> 30 63 M Lung squamous cell carcinoma, moderately differentiated 0/22 T2bN0M0 IIA 130 6 " class="fd_image"> 31 59 M Lung squamous cell carcinoma, moderately differentiated 3/21 T2aN1M0 IIA 131 6 " class="fd_image"> 32 62 M Lung squamous cell carcinoma, poorly differentiated 0/50 T4N0M0 IIIA 132 6 " class="fd_image"> 33 66 M Lung large cell neuroendocrine carcinoma 0/38 T3N0M0 IIB 133 6 " class="fd_image"> 34 58 M Lung squamous cell carcinoma, moderately differentiated 2/18 T1bN1M0 IIA 134 6 " class="fd_image"> 35 55 F Lung squamous cell carcinoma, poorly differentiated 1/3 T2aN2M0 IIIA 135 6 " class="fd_image"> 36 63 M Lung squamous cell carcinoma, well differentiated 8/28 T2aN2M0 IIIA 136 6 " class="fd_image"> 37 81 M Lung squamous cell carcinoma, well differentiated 0/17 T2aN0M0 IB 137 6 " class="fd_image"> 38 54 M Lung squamous cell carcinoma, moderately differentiated 1/33 T2aN1M0 IIA 138 6 " class="fd_image"> 39 49 M Lung squamous cell carcinoma, well differentiated 0/19 T2aN0M0 IB 139 6 " class="fd_image"> 40 68 M Lung squamous cell carcinoma, poorly differentiated 0/22 T3N0M0 IIB 140 6 " class="fd_image"> 41 60 M Lung squamous cell carcinoma, poorly differentiated 0/22 T2aN0M0 IB 141 6 " class="fd_image"> 42 65 M Lung large cell carcinoma 0/33 T2aN0M0 IB 142 6 " class="fd_image"> 43 51 M Lung bronchioloalveolar carcinoma, mucinous 1/11 T1bN1M0 IIA 143 6 " class="fd_image"> 44 56 M Lung squamous cell carcinoma, well differentiated 4/32 T2aN2M0 IIIA 144 6 " class="fd_image"> 45 46 M Lung squamous cell carcinoma, moderately differentiated 1/25 T2aN1M0 IIA 145 6 " class="fd_image"> 46 71 M Lung squamous cell carcinoma, moderately differentiated 0/21 T2aN0M0 IB 146 6 " class="fd_image"> 47 69 M Lung squamous cell carcinoma, poorly differentiated 0/11 T2aN0M0 IB 147 6 " class="fd_image"> 48 58 M Lung squamous cell carcinoma, well differentiated 0/24 T2bN0M0 IIA 148 6 " class="fd_image"> 49 62 M Lung bronchioloalveolar carcinoma, non-mucinous 2/24 T1aN1M0 IIA 149 6 " class="fd_image"> 50 71 M Lung squamous cell carcinoma, well differentiated 5/40 T2bN1M0 IIB 150 6 " class="fd_image"> 51 65 M Lung squamous cell carcinoma, moderately differentiated 0/28 T3N0M0 IIB 151 6 " class="fd_image"> 52 67 M Lung squamous cell carcinoma, poorly differentiated 0/12 T2aN0M0 IB 152 6 " class="fd_image"> 53 64 M Lung squamous cell carcinoma, poorly differentiated 0/14 T3N0M0 IIB 153 6 " class="fd_image"> 54 63 M Lung carcinosarcoma 0/14 T2aN0M0 IB 154 6 " class="fd_image"> 55 69 M Lung squamous cell carcinoma, moderately differentiated 0/20 T2aN0M0 IB 155 6 " class="fd_image"> 56 33 F Lung adenocarcinoma, moderately differentiated 0/6 T2aN0M0 IB 156 6 " class="fd_image"> 57 60 F Lung adenocarcinoma, well differentiated 22/22 T3N2M0 IIIA 157 6 " class="fd_image"> 58 68 M Lung adenocarcinoma, moderately differentiated 0/12 T2aN0M0 IB 158 6 " class="fd_image"> 59 41 F Lung adenocarcinoma, moderately differentiated 2/15 T3N2M0 IIIA 159 6 " class="fd_image"> 60 . . Carbon . . . .

Reviewed Applications	Read 1 Review rated 5 using NBP2-30277 in the following application: Immunocytochemistry
Publications	ReadPublications using NBP2-30277 in the following applications: FISH 1 publication IHC 1 publication IHC-P 5 publications

Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 【详细说明】  Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 上海普迈生物科技有限公司签约代理      欢迎下载下面的资料以了解此产品的相关信息！预询产品订购信息  上海普迈生物致力于提供zui高质量的产品和服务组织形态学研究与竞争力的产品 产品和服务,有相关产品的问题请直接 期货每周下午5点前发定单，正常到上海时间为3-4周 现市区2天内送到，外地以快递为准 敬请关注！ ：   :www.pumaibio.com :pumaibio :（直接客户） （经销商） 促销etonbio、polysciences、Mattek、trevigen、Chromogenix、cyguns、IrvineScientific、Innovative Cell Technologies、enzo、novus、immunochemistry、eylabs、Polyplus、NIBSC、ALZET、hitobiotec、sutter instrument、mirus、StressMarq、Avanti、jena bioscience、Neuro Probe、tedpella、avanti、Rockland、CAYMAN、transgenomic、BioLegend、ambion、omicronbio、 Assaybiotech、chondrex、lc?laboratories、cosmobio、megazyme、NeoMarkers、BTI、eylabs、berryassoc、cellagentech、TOCRIS、Relia Tech、SouthernBiotech、Biosearch technology、Lumiprobe、StemCells?Inc、biovendor、NORGEN、alomone、jena?bioscience、Gracebio、Eurogentec、Gelcompany?、invitrogen、gene?bridges、MRC-Holland、laysanbio